Mustang Bio (MBIO) Competitors $1.58 0.00 (0.00%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.62 +0.04 (+2.53%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. LVTX, GBIO, TELO, XFOR, PLUR, ESLA, JATT, SCYX, OKUR, and SNTIShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include LAVA Therapeutics (LVTX), Generation Bio (GBIO), Telomir Pharmaceuticals (TELO), X4 Pharmaceuticals (XFOR), Pluri (PLUR), Estrella Immunopharma (ESLA), JATT Acquisition (JATT), SCYNEXIS (SCYX), OnKure Therapeutics (OKUR), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Its Competitors LAVA Therapeutics Generation Bio Telomir Pharmaceuticals X4 Pharmaceuticals Pluri Estrella Immunopharma JATT Acquisition SCYNEXIS OnKure Therapeutics Senti Biosciences Mustang Bio (NASDAQ:MBIO) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Do institutionals and insiders believe in MBIO or LVTX? 10.0% of Mustang Bio shares are held by institutional investors. 0.2% of Mustang Bio shares are held by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher valuation & earnings, MBIO or LVTX? Mustang Bio has higher earnings, but lower revenue than LAVA Therapeutics. LAVA Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMustang BioN/AN/A-$15.75M-$78.00-0.02LAVA Therapeutics$11.98M3.32-$25.11M-$1.05-1.44 Do analysts prefer MBIO or LVTX? LAVA Therapeutics has a consensus price target of $2.69, indicating a potential upside of 77.81%. Given LAVA Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LAVA Therapeutics is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LAVA Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is MBIO or LVTX more profitable? Mustang Bio's return on equity of 0.00% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mustang BioN/A N/A -29.49% LAVA Therapeutics N/A -106.29%-38.24% Does the media favor MBIO or LVTX? In the previous week, LAVA Therapeutics had 1 more articles in the media than Mustang Bio. MarketBeat recorded 2 mentions for LAVA Therapeutics and 1 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 1.91 beat LAVA Therapeutics' score of 0.45 indicating that Mustang Bio is being referred to more favorably in the media. Company Overall Sentiment Mustang Bio Very Positive LAVA Therapeutics Neutral Which has more risk and volatility, MBIO or LVTX? Mustang Bio has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. SummaryMustang Bio beats LAVA Therapeutics on 7 of the 13 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.44M$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-0.0221.1676.3126.51Price / SalesN/A446.35523.55123.58Price / CashN/A45.4037.1760.46Price / Book-0.759.6213.666.29Net Income-$15.75M-$53.28M$3.28B$270.51M7 Day Performance12.06%1.01%0.83%1.95%1 Month Performance-10.73%4.58%4.62%6.33%1 Year Performance-87.97%8.35%80.94%25.63% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio1.0195 of 5 stars$1.58flatN/A-87.9%$11.44MN/A-0.02100Positive NewsLVTXLAVA Therapeutics1.6402 of 5 stars$1.55-1.3%$2.69+73.2%-12.0%$41.30M$11.98M-1.4860Short Interest ↑GBIOGeneration Bio4.0352 of 5 stars$5.83-2.7%$10.67+83.0%-76.1%$40.35M$19.89M-0.54150Positive NewsShort Interest ↓TELOTelomir Pharmaceuticals2.1047 of 5 stars$1.23-0.8%$15.00+1,119.5%-78.3%$40.03MN/A-2.281XFORX4 Pharmaceuticals4.6302 of 5 stars$3.39-3.1%$34.17+907.9%-83.8%$39.93M$2.56M-0.2380News CoveragePositive NewsShort Interest ↓Gap UpPLURPluri2.7119 of 5 stars$4.73-5.8%$12.00+153.7%-5.0%$39.51M$330K-0.86150ESLAEstrella Immunopharma2.6643 of 5 stars$1.00-4.8%$16.00+1,500.0%+15.5%$38.92MN/A-3.85N/AGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$2.20+6.3%N/A-48.1%$37.95MN/A0.003High Trading VolumeSCYXSCYNEXIS1.6094 of 5 stars$0.92+3.0%N/A-35.0%$37.31M$3.26M-2.2960Positive NewsGap DownOKUROnKure Therapeutics3.6285 of 5 stars$2.63-4.4%$32.33+1,129.4%N/A$37.21MN/A-0.55N/ASNTISenti Biosciences3.3749 of 5 stars$1.32-5.0%$8.50+543.9%-52.4%$36.36M$2.56M-0.154Positive NewsShort Interest ↓ Related Companies and Tools Related Companies LVTX Alternatives GBIO Alternatives TELO Alternatives XFOR Alternatives PLUR Alternatives ESLA Alternatives JATT Alternatives SCYX Alternatives OKUR Alternatives SNTI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
